Vitro Diagnostics (OTCMKTS:VODG) vs. HilleVax (NASDAQ:HLVX) Financial Review

Vitro Diagnostics (OTCMKTS:VODG) and HilleVax (NASDAQ:HLVX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Vitro Diagnostics and HilleVax’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vitro Diagnostics	-531.95%	N/A	-149.85%
HilleVax	N/A	-67.27%	-51.99%

Insider & Institutional Ownership

86.4% of HilleVax shares are owned by institutional investors. 27.7% of Vitro Diagnostics shares are owned by company insiders. Comparatively, 71.1% of HilleVax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Vitro Diagnostics and HilleVax, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vitro Diagnostics	0	0	0	0	0.00
HilleVax	0	6	0	0	2.00

HilleVax has a consensus target price of $3.00, suggesting a potential upside of 72.41%. Given HilleVax’s stronger consensus rating and higher possible upside, analysts plainly believe HilleVax is more favorable than Vitro Diagnostics.

Earnings & Valuation

This table compares Vitro Diagnostics and HilleVax”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vitro Diagnostics	$1.86 million	N/A	-$9.87 million	($2.21)	-0.18
HilleVax	N/A	N/A	-$123.57 million	($3.10)	-0.56

Vitro Diagnostics has higher revenue and earnings than HilleVax. HilleVax is trading at a lower price-to-earnings ratio than Vitro Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

HilleVax beats Vitro Diagnostics on 6 of the 11 factors compared between the two stocks.

About Vitro Diagnostics

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.

About HilleVax

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.